Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1964 2
1971 1
1973 1
1974 1
1979 2
1980 1
1983 1
1984 3
1985 3
1988 1
1991 1
1993 1
1994 1
1995 2
1996 3
1997 3
1998 3
1999 4
2000 5
2001 3
2002 3
2003 8
2004 3
2005 3
2006 5
2007 3
2008 3
2009 4
2010 5
2011 19
2012 15
2013 10
2014 6
2015 9
2016 11
2017 13
2018 16
2019 18
2020 18
2021 17
2022 9
2023 12
2024 17
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Results by year

Filters applied: . Clear all
Page 1
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Among authors: james lp. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
Acetaminophen-induced hepatotoxicity.
James LP, Mayeux PR, Hinson JA. James LP, et al. Drug Metab Dispos. 2003 Dec;31(12):1499-506. doi: 10.1124/dmd.31.12.1499. Drug Metab Dispos. 2003. PMID: 14625346 Review.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Shaw AT, et al. Among authors: james lp. Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23. Lancet Oncol. 2017. PMID: 29074098 Free PMC article. Clinical Trial.
Mitochondrial pharmacology: its future is now.
Szeto HH, James LP, Atkinson AJ. Szeto HH, et al. Among authors: james lp. Clin Pharmacol Ther. 2014 Dec;96(6):629-33. doi: 10.1038/clpt.2014.177. Clin Pharmacol Ther. 2014. PMID: 25399706
Scientia pro bono humani generis: Science for the benefit of humanity.
James LP, Kimberly R, Lindsell CJ, Meinzen-Derr JK, O'Hara R. James LP, et al. J Clin Transl Sci. 2024 Feb 20;8(1):e29. doi: 10.1017/cts.2023.696. eCollection 2024. J Clin Transl Sci. 2024. PMID: 38384907 Free PMC article. No abstract available.
245 results